Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation Has Unique Features and an Association with Engrafting Unit-to-Recipient HLA Match

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 6, 2013, Pages 904-911

  Ponce, D M ^a,b   Gonzales, A ^a   Lubin, M ^a   Castro Malaspina, H ^a,b   Giralt, S ^a,b   Goldberg, J D ^a,b   Hanash, A M ^a   Jakubowski, A ^a,b   Jenq, R ^a,b   Papadopoulos, E B ^a,b   Perales, M A ^a,b   van den Brink, M R M ^a,b   Young, J W ^a,b   Boulad, F ^a   O'Reilly, R J ^a   Prockop, S ^a   Small, T N ^a   Scaradavou, A ^a   Kernan, N A ^a   Stevens, C E ^a   Barker, J N ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cord blood transplantation; Graft versus host disease; HLA match

Indexed keywords

BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DRB1 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE BIPHENOTYPIC LEUKEMIA; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGE DISTRIBUTION; ARTICLE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; DOUBLE UNIT CORD BLOOD TRANSPLANTATION; FEMALE; GENE FREQUENCY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LATE GRAFT VERSUS HOST DISEASE; MAJOR CLINICAL STUDY; MALE; MULTINUCLEAR CELL; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; BUDESONIDE; CALCINEURIN; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL TRACT; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYELOABLATIVE AGONISTS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84877910561     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.02.008     Document Type: Article

References (48)

1. Eapen M., Rubinstein P., Zhang M.J., et al. Comparison of outcomes after transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia. Lancet 2007, 369:1947-1954.
2. Eapen M., Rocha V., Sanz G., et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: A retrospective analysis. Lancet Oncol 2010, 11:653-660.
3. MacMillan M.L., Weisdorf D.J., Brunstein C.G., et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009, 113:2410-2415.
4. Ponce D.M., Zheng J., Gonzales A.M., et al. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:1316-1326.
5. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: Relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
6. Chen Y.B., Aldridge J., Kim H.T., et al. Reduced-intensity conditioning stem cell transplantation: Comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant 2012, 18:805-812.
7. Barker J.N., Byam C., Scaradavou A. How I treat: The selection and acquisition of unrelated cord blood grafts. Blood 2011, 117:2332-2339.
8. Barker J.N., Abboud M., Rice R.D., et al. A " no-wash" albumin-dextran dilution strategy for cord blood unit thaw: High rate of engraftment and a low incidence of serious infusion reactions. Biol Blood Marrow Transplant 2009, 15:1596-1602.
9. Sauter C., Abboud M., Jia X., et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011, 17:1460-1471.
10. Jacobson P.A., Huang J., Wu J., et al. Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant 2010, 16:421-429.
11. Avery S., Shi W., Lubin M., et al. Influence of infused cell dose and HLA-match on engraftment after double-unit cord blood allografts. Blood 2011, 117:3277-3285.
12. Barker J.N., Byam C.E., Kernan N.A., et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. Biol Blood Marrow Transplant 2010, 16:1541-1548.
13. Avery S., Voss M.H., Gonzales A.M., et al. Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation. Bone Marrow Transplant 2011, 47:1056-1060.
14. Rowlings P.A., Przepiorka D., Klein J.P., et al. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol 1997, 97:855-864.
15. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005, 11:945-956.
16. Copelan E., Casper J.T., Carter S.L., et al. A scheme for defining cause of death and its application in the T cell depletion trial. Biol Blood Marrow Transplant 2007, 13:1469-1476.
17. MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
18. Levine J.E., Logan B., Wu J., et al. Graft-versus-host disease treatment: Predictors of survival. Biol Blood Marrow Transplant 2010, 16:1693-1699.
19. Alsultan A., Giller R.H., Gao D., et al. GVHD after unrelated cord blood transplant in children: Characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplant 2011, 46:668-675.
20. Petrovic A., Alpdogan O., Willis L.M., et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood 2004, 103:1542-1547.
21. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 2005, 105:4191-4199.
22. Reshef R., Luger S., Hexner E.O., et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012, 367:135-145.
23. Waldman E., Lu S.X., Hubbard V.M., et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood 2006, 107:1703-1711.
24. Bucher C., Koch L., Vogtenhuber C., et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood 2009, 114:5375-5384.
25. Hanash A.M., Kappel L.W., Yim N.L., et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood 2011, 118:446-455.
26. Hippen K.L., Bucher C., Schirm D.K., et al. Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes. Blood 2012, 119:619-628.
27. Betts B.C., Abdel-Wahab O., Curran S.A., et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood 2011, 118:5330-5339.
28. Hanash A.M., Dudakov J.A., Hua G., et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012, 37:339-350.
29. Arora M., Nagaraj S., Wagner J.E., et al. Chronic graft versus host disease following unrelated donor hematopoietic stem cell transplantation: Higher response rate in recipients of unrelated donor umbilical cord blood. Biol Blood Marrow Transplant 2007, 13:1145-1152.
30. Ibrahim R.B., Abidi M.H., Cronin S.M., et al. Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:395-405.
31. Bertz H., Afting M., Kreisel W., et al. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999, 24:1185-1189.
32. Andree H., Hilgendorf I., Leithaeuser M., et al. Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD. Bone Marrow Transplant 2008, 42:541-546.
33. Raaska K., Niemi M., Neuvonen M., et al. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. Clin Pharmacol Ther 2002, 72:362-369.
34. Arai S., Jagasia M., Storer B., et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011, 118:4242-4249.
35. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
36. Laughlin M.J., Eapen M., Rubinstein P., et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265-2275.
37. Barker J.N., Scaradavou A., Stevens C.E. Combined effect of total nucleated cell dose and HLA-match on transplant outcome in 1061 cord blood recipients with hematological malignancies. Blood 2010, 115:1843-1849.
38. Jagasia M., Arora M., Flowers M.E., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
39. Sanz J., Boluda J.C., Martin C., et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012, 47:1287-1293.
40. Brunstein C.G., Weisdorf D.J., Defor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of anti-thymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006, 108:2874-2880.
41. Cutler C., Stevenson K., Kim H.T., et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011, 46:659-667.
42. Komanduri K.V., St.John L.S., de Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110:4543-4551.
43. Brunstein C., Barker J.N., Weisdorf D.J., et al. Umbilical cord blood transplantation after non-myeloablative conditioning: Impact on transplant outcomes in 110 adults with hematological disease. Blood 2007, 110:3064-3070.
44. Soiffer R.J., Lerademacher J., Ho V., et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011, 117:6963-6970.
45. Levine J.E., Paczesny S., Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012, 18:S116-S124.
46. Harris A.C., Ferrara J.L., Braun T.M., et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 2012, 119:2960-2963.
47. Levine J.E., Logan B.R., Wu J., et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: A Blood and Marrow Transplant Clinical Trials Network study. Blood 2012, 119:3854-3860.
48. Delaney M., Cutler C.S., Haspel R.L., et al. High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion 2009, 49:995-1002.